Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation

Papers of special note have been highlighted as: • of interest

References

• 1. Park K, Tan EH, O'Byrne K et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a Phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17(5), 577–589 (2016).
  Medline CASGoogle Scholar
• 2. Wu YL, Cheng Y, Zhou X et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase III trial. Lancet Oncol. 18(11), 1454–1466 (2017). • A Phase III trial of second generation (dacomitinib) vs first-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI), which showed improved progression-free survival and suggested better overall survival.
  Medline CASGoogle Scholar
• 3. Soria JC, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113–125 (2018).
  Medline CASGoogle Scholar
• 4. Ramalingam SS, Vansteenkiste J, Planchard D et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41–50 (2020). • A Phase III trial of osimertinib (third generation) vs first-generation EGFR-TKI, which showed improved progression-free survival and overall survival.
  Medline CASGoogle Scholar
• 5. Mok TS, Wu YL, Ahn MJ et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376(7), 629–640 (2017).
  Medline CASGoogle Scholar
• 6. Leonetti A, Sharma S, Minari R et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small-cell lung cancer. Br. J. Cancer 121(9), 725–737 (2019).
  MedlineGoogle Scholar
• 7. Gray JE, Okamoto I, Sriuranpong V et al. Tissue and Plasma EGFR mutation analysis in the FLAURA trial: osimertinib vs comparator EGFR-TKI as first-line treatment in patients with EGFR mutated advanced NSCLC. Clin. Cancer Res. 25(22), 6644–6652 (2019).
  Medline CASGoogle Scholar
• 8. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240–2247 (2013).
  Medline CASGoogle Scholar
• 9. Oxnard GR, Arcila ME, Sima CS et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin. Cancer Res. 17, 1616–1622 (2017).
  Google Scholar
• 10. Cabanero M, Tsao MS. Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer. Curr. Oncol. 25(Suppl. 1), S38–S44 (2018).
  Medline CASGoogle Scholar
• 11. Li X, Zhou C. Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small-cell lung cancer. Oncotarget 8(59), 100801–100818 (2017).
  MedlineGoogle Scholar
• 12. Wang ZF, Ren SX, Li W, Gao GH. Frequency of the acquired resistant mutation T790 M in non-small-cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. BMC Cancer. 18(1), 148 (2018).
  Medline CASGoogle Scholar
• 13. Nosaki K, Satouchi M, Kurata T et al. Rebiopsy status among non-small-cell lung cancer patients in Japan: a retrospective study. Lung Cancer 101, 1–8 (2016). • Shows real-world efficacy of rebiopsy in detecting T790M mutation in EGFR-mutant non-small-cell lung cancer.
  MedlineGoogle Scholar
• 14. Zhou J, Zhao C, Zhao J et al. Rebiopsy and liquid biopsy for patients with non-small-cell lung cancer after EGFR-tyrosine kinase inhibitor failure. Thorac. Cancer 10(4), 957–965 (2019).
  Medline CASGoogle Scholar
• 15. Hotta K, Ninomiya K, Ichihara E et al. Significance of rebiopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. Int. J. Clin. Oncol. 24(1), 41–45 (2019).
  Medline CASGoogle Scholar
• 16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 17. Oellerich M, Christenson RH, Beck J et al. Plasma EGFR mutation testing in non-small-cell lung cancer: a value proposition. Clin. Chim. Acta 495, 481–486 (2019).
  Medline CASGoogle Scholar
• 18. Saarenheimo J, Eigeliene N andersen H et al. The value of liquid biopsies for guiding therapy decisions in non-small-cell lung cancer. Front. Oncol. 9, 129 (2019).
  MedlineGoogle Scholar
• 19. Akamatsu H, Katakami N, Okamoto I et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci. 109(6), 1930–1938 (2018). • Toxicity and efficacy of salvage osimertinib in Japanese subset in AURA3 study, which corresponds to the patients in our study.
  Medline CASGoogle Scholar
• 20. Hirashima T, Satouchi M, Hida T et al. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: a pooled subgroup analysis. Cancer Sci. 110(9), 2884–2893 (2019).
  Medline CASGoogle Scholar
• 21. Mu Y, Xing P, Hao X et al. Real-world data of osimertinib in patients with pretreated non-small-cell lung cancer: a retrospective study. Cancer Manag. Res. 11, 9243–9251 (2019).
  Medline CASGoogle Scholar
• 22. Zhou J, Zhao C, Zhao J et al. Rebiopsy and liquid biopsy for patients with non-small-cell lung cancer after EGFR-tyrosine kinase inhibitor failure. Thorac. Cancer. 10(4), 957–965 (2019).
  Medline CASGoogle Scholar